Tarsons Products working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY22 and earlierAlpha Plus

336.20×	336.20×	359.20×	571.53×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
71.27×	71.27×	73.25×	88.47×
47.34×	47.34×	42.79×	53.92×
360.13×	360.13×	389.66×	606.08×
282.22×	270.15×	5.87×	13.40×
0.37×	0.37×	0.38×	0.35×
8.27×	8.27×	3.84×	2.41×
1.00×	1.00×	1.03×	1.03×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

TARSONS₹298.15

Tarsons Products Limited

· Pharma & Health

₹ CrorePeersFISCHER LAXMIDENTL FABTECH GKBMcap ₹1,586 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	—	571.53	359.20	336.20	336.20
Receivable Days (DSO)	—	88.47	73.25	71.27	71.27
Payable Days (DPO)	—	53.92	42.79	47.34	47.34
Cash Conversion Cycle (days)	—	606.08	389.66	360.13	360.13
Working Capital Turnover	—	13.40	5.87	270.15	282.22
Asset Turnover	—	0.35	0.38	0.37	0.37
Cash Conversion (CFO/Net Income)	—	2.41	3.84	8.27	8.27
CFO/EBITDA	—	1.03	1.03	1.00	1.00

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.